Maria-belen B. Vidriales

Salamanca, CL, Spain

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications

Impact of hematopoietic cell transplantation and quizartinib in patients with newly diagnosed FLT3-internal tandem duplication-negative acute myeloid leukemia: results from the QUIWI study.

Impact of hematopoietic cell transplantation and quizartinib in patients with newly diagnosed FLT3-internal tandem duplication-negative acute myeloid leukemia: results from the QUIWI study.

Journal: Haematologica
Published: March 10, 2026

Erratum: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Erratum: Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 01, 2025

Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 13, 2025

Targeting NOX2 and glycolytic metabolism as a therapeutic strategy in acute myeloid leukaemia.

Targeting NOX2 and glycolytic metabolism as a therapeutic strategy in acute myeloid leukaemia.

Journal: Biomarker research
Published: September 19, 2024

Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia.

Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia.

Journal: Blood neoplasia
Published: February 20, 2024

Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC).

Ibrutinib followed by ofatumumab consolidation in previously untreated patients with chronic lymphocytic leukemia (CLL): GELLC-7 trial from the Spanish group of CLL (GELLC).

Journal: EClinicalMedicine
Published: January 12, 2024

Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.

Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.

Journal: British journal of haematology
Published: January 20, 2023

Eltrombopag increases the hematopoietic supporting ability of mesenchymal stem/stromal cells.

Eltrombopag increases the hematopoietic supporting ability of mesenchymal stem/stromal cells.

Journal: Therapeutic advances in hematology
Published: June 15, 2022

Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.

Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.

Journal: Blood advances
Published: August 14, 2020

Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.

Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.

Journal: Leukemia
Published: July 23, 2020

Measures to Maintain a SARS-CoV-2 Negative Inpatient Hematological Unit in the Midst of the COVID-19 Pandemic.

Measures to Maintain a SARS-CoV-2 Negative Inpatient Hematological Unit in the Midst of the COVID-19 Pandemic.

Journal: Frontiers in medicine
Published: May 24, 2020

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.

Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.

Journal: Blood
Published: May 04, 2020
Showing 1-12 of 35

Last Updated: 09/26/2026